Momenta Pharmaceuticals — Deal History & Benchmarks

Total Deals

Across 1 therapeutic area

Total Deal Value

$13B

Cumulative transaction value

Most Active Year

2020

2 deals closed

Primary TA

Immunology & Autoimmune

100% of deal activity

Model Your Deal

Market Analysis

Momenta Pharmaceuticals has been involved in 2 transactions totaling $13B across Immunology & Autoimmune. As a licensor (out-licensor), they have demonstrated an active acquisition strategy.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How many deals has Momenta Pharmaceuticals done?

Momenta Pharmaceuticals has completed 2 verified transactions tracked in our database, spanning from 2020 to 2020. These deals have a combined value of $13B.

What is Momenta Pharmaceuticals's typical deal structure?

Based on 2 deals, Momenta Pharmaceuticals's transactions show a median upfront payment of $6.5B. Their most common deal type is acquisition, reflecting an active acquisition strategy.

What therapeutic areas does Momenta Pharmaceuticals focus on?

Momenta Pharmaceuticals focuses on Immunology & Autoimmune, representing 100% of their tracked deals.

PRO